Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov; 13(11):927-35.

View in: PubMed

subject areas

Adenine
Adult
CD4 Lymphocyte Count
Dideoxynucleosides
Double-Blind Method
Drug Administration Schedule
Drug Combinations
Female
Heterocyclic Compounds, 3-Ring
HIV Infections
HIV Integrase Inhibitors
HIV-1
Humans
Kaplan-Meier Estimate
Lamivudine
Male
Organophosphonates
Oxazines
Piperazines
Pyridones
Pyrrolidinones
Raltegravir Potassium
RNA, Viral
Tenofovir

authors with profiles

Helmut Albrecht